Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients

Hepatology

Volumn 63, Issue 6, 2016, Pages 1968-1976

  Bossen, Lars ^a   Krag, Aleksander ^b   Vilstrup, Hendrik ^a   Watson, Hugh ^c   Jepsen, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; SODIUM;

ADULT; ARTICLE; ASCITES; BACTERIAL INFECTION; CHILD PUGH SCORE; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATORENAL SYNDROME; HOSPITALIZATION; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT DECISION MAKING; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SODIUM BLOOD LEVEL; STOMACH VARICES BLEEDING;

EID: 84978221109     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28352     Document Type: Article

References (33)

1. Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med 1981;305:1371-1374.
2. Thiele M, Krag A, Rohde U, Gluud LL. Meta-analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. Aliment Pharmacol Ther 2012;35:1155-1165.
3. Gluud LL, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev 2012;8:CD004544.
4. Giannelli V, Lattanzi B, Thalheimer U, Merli M. Beta-blockers in liver cirrhosis. Ann Gastroenterol 2014;27:20-26.
5. Triantos C, Kalafateli M. Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis. World J Hepatol 2014;6:363-369.
6. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008;48(Suppl. 1):S68-S92.
7. Serste T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017-1022.
8. Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe? Hepatology 2010;52:811-813.
9. Senzolo M, Nadal E, Cholongitas E, Burroughs AK. Is hydrophobia necessary for the hepatologist prescribing nonselective beta-blockers in cirrhosis? Hepatology 2011;53:2149-2150.
10. Krag A, Madsen BS. To block, or not to block in advanced cirrhosis and ascites: that is the question. Gut 2015;64:1015-1017.
11. Robins A, Bowden A, Watson W, Smith F, Gelson W, Griffiths W. Beta-blockers in cirrhosis patients with refractory ascites. Hepatology 2014;59:2054-2055.
12. Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010;59:105-110.
13. Serste T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011;55:794-799.
14. Kimer N, Feineis M, Moller S, Bendtsen F. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. Scand J Gastroenterol 2014:1-9.
15. Leithead JA, Rajoriya N, Tehami N, Hodson J, Gunson BK, Tripathi D, et al. Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut 2015;64:1111-1119.
16. Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014;146:1680-1690.
17. Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012;61:967-969.
18. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Postgrad Med J 2009;85:44-54.
19. Ge PS, Runyon BA. When should the beta-blocker window in cirrhosis close? Gastroenterology 2014;146:1597-1599.
20. Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012;61:108-116.
21. Rothman KJ. Dealing with biases. In: Epidemiology: An Introduction. 2nd ed. New York: Oxford University Press; 2012:124-147.
22. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 2011;26:546-550.
23. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922-938.
24. Tripathi D, Stanley AJ, Hayes PC, Patch D, Millson C, Mehrzad H, et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015;64:1680-1794.
25. Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987;317:856-861.
26. Italian Multicenter Project for Propranolol in Prevention of Bleeding. Propranolol for prophylaxis of bleeding in cirrhotic patients with large varices: a multicenter, randomized clinical trial. Hepatology 1988;8:1-5.
27. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991;324:1532-1538.
28. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475-505.
29. Agustin A, Javier Z. Beta-blockers in patients with cirrhosis and refractory ascites. Hepatology 2011;53:1783.
30. Lo GH. Effects of beta-blockers on survival for patients with cirrhosis and refractory ascites. Hepatology 2011;53:1068-1069.
31. Thevenot T, Cervoni JP, Monnet E, Sheppard F, Martino VD. Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites? Hepatology 2011;53:715-716.
32. Dales LG, Ury HK. An improper use of statistical significance testing in studying covariables. Int J Epidemiol 1978;7:373-375.
33. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.